NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes

Nature Communications

Volumn 6, Issue , 2015, Pages

  Sosa, Maria Soledad ^a   Parikh, Falguni ^a   Maia, Alexandre Gaspar ^a   Estrada, Yeriel ^a   Bosch, Almudena ^a   Bragado, Paloma ^a   Ekpin, Esther ^a   George, Ajish ^a   Zheng, Yang ^a   Lam, Hung Ming ^b   Morrissey, Colm ^b   Chung, Chi Yeh ^a   Farias, Eduardo F ^a   Bernstein, Emily ^a   Aguirre Ghiso, Julio A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DECITABINE; NR2F1 PROTEIN; ORPHAN NUCLEAR RECEPTOR; RETINOIC ACID; RETINOIC ACID RECEPTOR BETA; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 1; HOMEODOMAIN PROTEIN; RETINOIC ACID RECEPTOR;

CANCER; CELLS AND CELL COMPONENTS; DNA; DORMANCY; GENE EXPRESSION; INHIBITION; MOLECULAR ANALYSIS; ORGANIC ACID; SURVIVAL; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CANCER INHIBITION; CHROMATIN; DORMANCY; EPIGENETICS; FEMALE; GENE EXPRESSION; GROWTH DISORDER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; UPREGULATION; ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; NUDE MOUSE; PROSTATE TUMOR; RNA INTERFERENCE; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COUP TRANSCRIPTION FACTOR I; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID; RNA INTERFERENCE; SOX9 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 84938626001     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7170     Document Type: Article

References (48)

1. Sosa, M. S., Avivar-Valderas, A., Bragado, P., Wen, H. C. & Aguirre-Ghiso, J. A. ERK1/2 and p38alpha/beta signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin. Cancer Res. 17, 5850-5857 (2011).
2. Sosa, M. S., Bragado, P. & Aguirre-Ghiso, J. A. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat. Rev. Cancer 14, 611-622 (2014).
3. Adam, A. P., et al. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Res. 69, 5664-5672 (2009).
4. Onder, T. T., et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 483, 598-602 (2012).
5. Marion, R. M., et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460, 1149-1153 (2009).
6. Bragado, P., et al. TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling. Nat. Cell Biol. 15, 1351-1361 (2013).
7. Kim, R. S., et al. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS ONE 7, e35569 (2012).
8. Qiu, Y., et al. Spatiotemporal expression patterns of chicken ovalbumin upstream promoter-transcription factors in the developing mouse central nervous system: evidence for a role in segmental patterning of the diencephalon. Proc. Natl Acad. Sci. USA 91, 4451-4455 (1994).
9. Zhuang, Y. & Gudas, L. J. Overexpression of COUP-TF1 in murine embryonic stem cells reduces retinoic acid-associated growth arrest and increases extraembryonic endoderm gene expression. Differentiation 76, 760-771 (2008).
10. Rada-Iglesias, A., et al. Epigenomic annotation of enhancers predicts transcriptional regulators of human neural crest. Cell Stem Cell 11, 633-648 (2012).
11. Fackler, M. J., et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res. 64, 4442-4452 (2004).
12. Ginos, M. A., et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res. 64, 55-63 (2004).
13. Richardson, A. L., et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9, 121-132 (2006).
14. Hou, J., et al. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy. J. Thorac. Oncol. 7, 105-114.
15. Grasso, C. S., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
16. Taylor, B. S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
17. Smits, B. M., et al. The gene desert mammary carcinoma susceptibility locus Mcs1a regulates Nr2f1 modifying mammary epithelial cell differentiation and proliferation. PLoS Genet. 9, e1003549 (2013).
18. Thompson, V. C., et al. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. Int. J. Cancer 131, 662-672 (2011).
19. Kim, J., et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 143, 313-324 (2010).
20. Aguirre-Ghiso, J. A., Ossowski, L. & Rosenbaum, S. K. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res. 64, 7336-7345 (2004).
21. Aguirre-Ghiso, J. A., Estrada, Y., Liu, D. & Ossowski, L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 63, 1684-1695 (2003).
22. Aguirre-Ghiso, J. A., Liu, D., Mignatti, A., Kovalski, K. & Ossowski, L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 12, 863-879 (2001).
23. Schewe, D. M. & Aguirre-Ghiso, J. A. ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proc. Natl Acad. Sci. USA 105, 10519-10524 (2008).
24. Liu, D., Aguirre Ghiso, J., Estrada, Y. & Ossowski, L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1, 445-457 (2002).
25. Aguirre Ghiso, J. A. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 21, 2513-2524 (2002).
26. Ossowski, L. & Reich, E. Changes in malignant phenotype of a human carcinoma conditioned by growth environment. Cell 33, 323-333 (1983).
27. Huang, S., et al. ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 15, 328-340 (2009).
28. Bragado, P., et al. Analysis of marker-defined HNSCC subpopulations reveals a dynamic regulation of tumor initiating properties. PLoS ONE 7, e29974 (2012).
29. Florenes, V. A., et al. TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1. Oncogene 13, 2447-2457 (1996).
30. Sang, L., Coller, H. A. & Roberts, J. M. Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science 321, 1095-1100 (2008).
31. Chery, L., et al. Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget 5, 9939-9951 (2014).
32. Husemann, Y., et al. Systemic spread is an early step in breast cancer. Cancer Cell 13, 58-68 (2008).
33. Lu, X., et al. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res. Treat. 108, 191-201 (2008).
34. Curtis, C., et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
35. Lin, B., et al. Orphan receptor COUP-TF is required for induction of retinoic acid receptor beta, growth inhibition, and apoptosis by retinoic acid in cancer cells. Mol. Cell. Biol. 20, 957-970 (2000).
36. Afonja, O., et al. RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition. Oncogene 21, 7850-7860 (2002).
37. Drivdahl, R., et al. Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9. Oncogene 23, 4584-4593 (2004).
38. Qiu, Y., Krishnan, V., Pereira, F. A., Tsai, S. Y. & Tsai, M. J. Chicken ovalbumin upstream promoter-transcription factors and their regulation. J. Steroid Biochem. Mol. Biol. 56, 81-85 (1996).
39. Ossowski, L., Russo, H., Gartner, M. & Wilson, E. L. Growth of a human carcinoma (HEp3) in nude mice: rapid and efficient metastasis. J. Cell. Physiol. 133, 288-296 (1987).
40. Ghiaur, G., et al. Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling. Proc. Natl Acad. Sci. USA 110, 16121-16126 (2013).
41. Purton, L. E., et al. RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J. Exp. Med. 203, 1283-1293 (2006).
42. Naka, H., Nakamura, S., Shimazaki, T. & Okano, H. Requirement for COUPTFI and II in the temporal specification of neural stem cells in CNS development. Nat. Neurosci. 11, 1014-1023 (2008).
43. Tsai, H. C., et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21, 430-446.
44. Aslakson, C. J. & Miller, F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399-1405 (1992).
45. Bosch, A., et al. Reversal by RARalpha agonist Am580 of c-Myc-induced imbalance in RARalpha/RARgamma expression during MMTV-Myc tumorigenesis. Breast Cancer Res. 14, R121 (2012).
46. Aguirre Ghiso, J. A., Kovalski, K. & Ossowski, L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147, 89-104 (1999).
47. Zijlstra, A., et al. A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res. 62, 7083-7092 (2002).
48. Gaspar-Maia, A., et al. MacroH2A histone variants act as a barrier upon reprogramming towards pluripotency. Nat. Commun. 4, 1565 (2013).